




viruses



an Open Access Journal by MDPI

Antiretroviral Drug Development and HIV Cure Research

Guest Editors:

Prof. Dr. Enzo Tramontano

Department of Life and
Environmental Sciences,
University of Cagliari, Cittadella
Universitaria di Monserrato
SS554, Monserrato, 09042
Cagliari, Italy

Prof. Dr. Ben Berkhout

Laboratory of Experimental
Virology, Department of Medical
Microbiology, University of
Amsterdam, Meibergdreef 15,
1105 AZ Amsterdam, The
Netherlands

Deadline for manuscript
submissions:

closed (30 June 2020)

Message from the Guest Editors

Dear Colleagues, Human immunodeficiency virus type 1 (HIV-1) establishes a persistent infection that results in acquired immunodeficiency syndrome (AIDS) if left untreated. Around 37 million people in the world live with HIV-1, with around 2 million new infections each year. While combined antiretroviral therapy (ART) has been shown to be very effective, inhibiting HIV-1 replication and preventing the development of AIDS, it has to be administered life-long, exposing the patients to possible side-effects. In addition, increasing emergence of resistance to ARV drugs could challenge ART efficacy, especially considering the international effort to reach 40% of HIV-infected people that live in developing countries and are yet to receive treatment. Therefore, despite ART effectiveness, the generation of new drugs against novel targets or with more favorable pharmacokinetics profiles and the development of novel delivery systems has to continue.

Prof. Enzo Tramontano

Prof. Dr. Ben Berkhout

Guest Editors



mdpi.com/si/30349

Special Issue



an Open Access Journal by MDPI

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication
Program, Center for Cancer
Research, National Cancer
Institute, Frederick, MD 21702-
1201, USA

Message from the Editor-in-Chief

Viruses (ISSN 1999-4915) is an open access journal which provides an advanced forum for studies of viruses. It publishes reviews, regular research papers, communications, conference reports and short notes. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers. The full experimental details must be provided so that the results can be reproduced. We also encourage the publication of timely reviews and commentaries on topics of interest to the virology community and feature highlights from the virology literature in the 'News and Views' section.

Electronic files or software regarding the full details of the calculation and experimental procedure, if unable to be published in a normal way, can be deposited as supplementary material.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **MEDLINE**, **PMC**, **Embase**, **PubAg**, **AGRIS**, and **other databases**.

Journal Rank: JCR - Q2 (Virology) / CiteScore - Q1 (Infectious Diseases)

Contact Us

Viruses Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/viruses
viruses@mdpi.com
[X@VirusesMDPI](https://twitter.com/VirusesMDPI)